Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 205

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 205
---
 are not required under law or under our amended and restated articles of association to
be exercised or taken by our shareholders, including the power to borrow money for company purposes.

Changes in Capital

Our amended and restated
articles of association to be in effect upon completion of this offering enable us to increase or reduce our share capital. Any such
change is subject to Israeli law and must be approved by a resolution duly passed by our shareholders at a general meeting. In addition,
transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient
retained earnings or profits, may require the approval of both our board of directors and an Israeli court.

Transfer Agent and Registrar

The transfer agent and
registrar for our Ordinary Shares is VStock Transfer, LLC. Its address is 18 Lafayette Place, Woodmere, New York 11598, and its telephone
number is (212) 828-8436.

Listing

Our Ordinary Shares have
been approved for listing on the NYSE American under the symbol “RGNT”. No assurance can be given that our application will
be approved or that a trading market will develop.

<div align='center'>123

DESCRIPTION OF THE SECURITIES WE ARE OFFERING</div>

Ordinary Shares

The material terms and provisions
of our Ordinary Shares are described under the caption “Description of Share Capital” in this prospectus.

<div align='center'>SHARES ELIGIBLE FOR FUTURE SALE</div>

Prior to this offering, no
public market existed for our Ordinary Shares. Sales of substantial amounts of our Ordinary Shares following this offering, or the perception
that these sales could occur, could adversely affect prevailing market prices of our Ordinary Shares and could impair our future ability
to obtain capital, especially through an offering of equity securities. Assuming that the underwriters do not exercise in full their
option to purchase additional Ordinary Shares and/or additional Warrants with respect to this offering and assuming no exercise of options
outstanding following this offering, we will have an aggregate of Ordinary Shares outstanding upon the closing of this offering. Of these
shares, the Ordinary Shares sold in this offering will be freely tradable without restriction or further registration under the Securities
Act, unless purchased by “affiliates” (as that term is defined under Rule 144 of the Securities Act, or Rule 144),
who may sell only the volume of shares described below and whose sales would be subject to additional restrictions described below.

The remaining Ordinary Shares
will